Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Report 2025

The phosphoinositide 3-kinase (PI3K) inhibitors market size has grown rapidly in recent years. It will grow from $1.38 billion in 2024 to $1.56 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to the increasing prevalence of cancer, growing research on targeted therapies, regulatory approvals for first-generation PI3K inhibitors, rising healthcare expenditure, and expanding clinical trials for hematologic malignancies.

The phosphoinositide 3-kinase (PI3K) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $2.55 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to the increasing demand for combination therapies, emergence of next-generation PI3K inhibitors with improved safety profiles, rising investment in cancer research and development, expansion of indications beyond oncology, and growing adoption of biomarkers for patient selection. Major trends in the forecast period include a shift toward dual and pan-isoform PI3K inhibitors, a growing preference for oral formulations over intravenous options, an increasing focus on overcoming resistance mechanisms, a rising integration of artificial intelligence in drug discovery, and an expanding role of PI3K inhibitors in immunotherapy combinations.

The forecast of 13.2% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder hematologic cancer care by inflating prices of phosphoinositide 3-kinase inhibitor drug substances like idelalisib and copanlisib developed in Japan and Belgium, resulting in delayed lymphoma treatment protocols and increased specialty oncology expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cancer and autoimmune diseases is expected to significantly drive the growth of the phosphoinositide 3-kinase (PI3K) inhibitors market in the coming years. Cancer, which involves uncontrolled cell growth, and autoimmune diseases, where the immune system mistakenly attacks the body's own tissues, are both on the rise. This is largely due to genetic predispositions, accumulated genetic mutations, and immune system dysregulation over time. PI3K inhibitors are essential in addressing the rising incidence of these diseases by targeting abnormal PI3K signaling pathways, which are implicated in tumor progression and immune system dysfunction. These inhibitors offer precision medicine approaches that improve treatment efficacy and patient outcomes. For example, the National Cancer Institute projected that the number of cancer survivors in the U.S. would rise from 18.1 million in 2022 to 22.5 million by 2032. This indicates a growing demand for treatments, including PI3K inhibitors, to manage cancer and autoimmune diseases, driving the market forward.

Leading companies in the PI3K inhibitors market are making significant strides in developing targeted therapies, including PI3K delta inhibitor treatments, to address diseases linked to dysregulated PI3K signaling. PI3K delta inhibitors specifically target the PI3K delta enzyme, which plays a crucial role in immune cell signaling. By inhibiting this enzyme, these therapies can help reduce inflammation, autoimmune responses, and certain blood cancers. For instance, in March 2023, the U.S. Food and Drug Administration (FDA) approved Joenja (leniolisib), the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. This approval marked a significant milestone in personalized medicine, offering a precision treatment approach to address immune dysfunction caused by genetic mutations in the PIK3CD or PIK3R1 genes. The approval of Joenja demonstrates how PI3K inhibitors are being used not just in oncology but in treating rare immunological disorders, underscoring the shift towards more targeted, individualized therapies in the market.

In October 2024, OnKure Therapeutics, a U.S.-based biopharmaceutical company, merged with Reneo Pharmaceuticals to create a combined entity focused on advancing mutant-selective PI3Kα inhibitors for cancer treatment. This merger, which involved a substantial financial commitment, aims to accelerate the development of precision medicines that specifically target mutant PI3Kα enzymes implicated in various cancers. PI3Kα inhibitors, which selectively target mutant forms of the PI3K alpha enzyme, are being explored as a potential treatment for cancers that have developed resistance to traditional therapies. The merger strengthens both companies’ positions in oncology and accelerates the clinical development of novel therapies, potentially transforming cancer treatment paradigms and expanding the PI3K inhibitors market.

Major players in the phosphoinositide 3-kinase (pi3k) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Boehringer Ingelheim, Genentech Inc., Incyte Corporation, Exelixis, Kura Oncology, TG Therapeutics Inc., Verastem Oncology.

North America was the largest region in the phosphoinositide 3-kinase (PI3K) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phosphoinositide 3-kinase (PI3K) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the phosphoinositide 3-kinase (PI3K) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phosphoinositide 3-kinase (PI3K) inhibitors market consists of sales of oral formulations, intravenous injections, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The phosphoinositide 3-kinase (PI3K) inhibitors market research report is one of a series of new reports that provides phosphoinositide 3-kinase (PI3K) inhibitors market statistics, including phosphoinositide 3-kinase (PI3K) inhibitors industry global market size, regional shares, competitors with a phosphoinositide 3-kinase (PI3K) inhibitors market share, detailed phosphoinositide 3-kinase (PI3K) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the phosphoinositide 3-kinase (PI3K) inhibitors industry. This phosphoinositide 3-kinase (PI3K) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Phosphoinositide 3-Kinase (PI3K) inhibitors are a class of drugs that target the PI3K enzyme, which plays a crucial role in regulating cell growth, survival, and metabolism. These inhibitors help control abnormal cell division and tumor growth, making them effective in treating various cancers, including breast cancer, leukemia, and lymphoma. PI3K inhibitors work by blocking signaling pathways that promote the survival and proliferation of cancer cells, ultimately slowing down or halting tumor progression.

The main types of PI3K inhibitors include isoform-selective inhibitors, pan-PI3K inhibitors, dual PI3K or mechanistic target of rapamycin (mTOR) inhibitors, and novel targeted inhibitors. Isoform-selective inhibitors are specialized compounds that selectively target and inhibit specific isoforms of an enzyme or protein, reducing off-target effects and improving therapeutic precision. These inhibitors are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. They are primarily used in cancer treatment, metabolic disorders, autoimmune diseases, and neurological disorders, with end-users including hospitals, research institutes, pharmaceutical companies, and contract research organizations (CROs).

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.